Skip to content
DataLookout
Menu

PAN-SELECTNCT07912606

D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Progression-free survival rate at 2 years
Timeframe: From randomization to 2 years after randomization

Secondary (12)

Recurrence-free survival rate at 2 years after surgery
Overall survival
Cumulative incidence of para-aortic lymph node region recurrence
R0 resection rate
Pathological complete response rate
Show 7 moreShow less
Number of examined and metastatic regional lymph nodes
Pathological positivity rate of No. 16 para-aortic lymph nodes in the experimental arm
Operative time
Estimated intraoperative blood loss
Postoperative length of hospital stay
Rate of Clavien-Dindo grade III or higher postoperative complications
All-cause postoperative mortality

Arms and interventions

D2 plus PANDExperimental

Participants undergo curative-intent gastrectomy with standard D2 lymphadenectomy plus systematic para-aortic lymph node dissection of No. 16a2 and No. 16b1. The No. 16 specimen is submitted separately for pathological examination.

D2 aloneExperimental

Participants undergo curative-intent gastrectomy with standard D2 lymphadenectomy without planned systematic dissection of No. 16a2 or No. 16b1. Rescue removal or dissection is permitted only when an intraoperative finding requires treatment for safety or curative intent, and the reason and extent are recorded.

Procedures: Gastrectomy with D2 lymphadenectomy plus para-aortic lymph node dissection, Gastrectomy with standard D2 lymphadenectomy

Sites

1 site in 1 country

  • The First Affiliated Hospital with Nanjing Medical UniversityNanjing, Jiangsu, China